Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - nilotinib - lewkimja, mjeloġenika, kronika, bcr-abl pożittiva - aġenti antineoplastiċi - tasigna huwa indikat għall-kura ta': pazjenti adulti u pedjatriċi li jkunu għadhom kif ġew dijanjostikati kromożoma pożittiva philadelphia lewkimja miloġenja kronika (cml) fil-fażi kronika,il-pazjenti pedjatriċi b'kromożoma pożittiva philadelphia b'cml fil-fażi kronika b'reżistenza jew intolleranza għal terapija ta ' qabel inkluża imatinib. tasigna huwa indikat għall-kura ta': pazjenti adulti u pedjatriċi li jkunu għadhom kif ġew dijanjostikati kromożoma pożittiva philadelphia lewkimja miloġenja kronika (cml) fil-fażi kronika,pazjenti adulti b'fażi kronika u b'fażi aċċellerata b'cml b'kromożoma pożittiva philadelphia b'reżistenza jew intolleranza għal terapija ta ' qabel inkluża imatinib. dejta dwar l-effikaċja f'pazjenti b'cml fi blast crisis mhijiex disponibbli,pazjenti pedjatriċi b'fażi kronika b'cml b'kromożoma pożittiva philadelphia b'reżistenza jew intolleranza għal terapija ta ' qabel inkluża imatinib.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva santé animale - benazepril hydrochloride, spironolactone - sistema kardjovaskulari - klieb - għat-trattament ta 'insuffiċjenza tal-qalb konġestiva kkawżata minn mard valvulari klementi deġenerattiv fil-klieb (b'appoġġ dijuretiku kif xieraq).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - ċitrat maropitiku - l-apparat alimentari u tal-metaboliżmu - dogs; cats - pilloli klieb: għall-prevenzjoni tad-dardir ikkawżat mill-kimoterapija. għall-prevenzjoni ta 'rimettar ikkaġunat minn mard tal-moviment. għall-prevenzjoni u t-trattament ta 'remettar, flimkien ma' cerenia soluzzjoni għall-injezzjoni u flimkien ma 'miżuri oħra ta' appoġġ. soluzzjoni għall-injectiondogs:għat-trattament u l-prevenzjoni ta ' dardir indotta mill-kimoterapija. għall-prevenzjoni ta 'rimettar ħlief dak imġiegħel minn mard tal-moviment. għat-trattament ta 'remettar, flimkien ma' miżuri oħra ta 'appoġġ. għall-prevenzjoni tal-perjodu dardir u r-rimettar u t-titjib fil-irkupru mill-loppju ġenerali, wara l-użu tal-μ-opiate tar-riċettur ta ' morfina. qtates: għall-prevenzjoni tar-rimettar u t-tnaqqis tad-dardir, ħlief dak imġiegħel minħabba mard tal-moviment. għat-trattament ta 'remettar, flimkien ma' miżuri oħra ta 'appoġġ.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetil fumarate - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international b. v. - tepoxalin - sistema musculo-skeletali - klieb - tnaqqis ta 'infjammazzjoni u eżenzjoni ta' uġigħ ikkawżat minn disturbi muskoloskeletali akuti u kroniċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

orion corporation - ropinirole hydrochloride - aġenti dopaminerġiċi, agonisti ta ' dopamine - klieb - l-induzzjoni tar-rimettar fil-klieb.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - pressjoni għolja - antagonisti ta 'angiotensin ii, sempliċi - hypertensiontreatment ta'l-ipertensjoni essenzjali fl-adulti. kardjovaskulari preventionreduction tal-morbidità kardjovaskulari f'pazjenti bi: - manifest aterotrombotiċi mard kardjovaskulari (passat ta ' mard koronarju tal-qalb, puplesija, jew mard arterjali periferali) jew;dijabete tat-tip 2 mellitus dokumentata-mira-ħsara fl-organi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan, amlodipine - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - it-trattament tal-ipertensjoni essenzjali fl-adulti:add-on therapytwynsta huwa indikat fl-adulti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina. is-sostituzzjoni therapyadult pazjenti li kienu qed jirċievu telmisartan u amlodipine minn pilloli separati jistgħu minflok ma jirċievu l-pilloli ta ' twynsta li fihom l-istess dożi tal-komponenti.